Crystagen research trail: defined EDP peptide — US8057810B2
Vladimir Khatskelevich Khavinson, Evgeny Iosifovich Grigoriev, Vladimir Victorivich Malinin, Galina Anatolievna Ryzhak · 2011 · US8057810B2 · patent family 38314259
Published 2011-11-15.
Reported patent results
Reported findings
Selected T-cell markers changed during EDP-containing care, without established clinical immune-rejuvenation outcomes.
EDP patent comparison in older adults aged 62–83: 38 receiving severity-adjusted adjunctive peptide and 32 conventional care.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| CD3-positive cells | 55.7 ± 2.6% after peptide-containing care versus 49.3 ± 2.2% conventional care; baseline 43.5 ± 2.3% | Immune-marker endpoint; significance annotation has an ambiguous comparator footnote |
| CD4/CD8 ratio | 1.4 after peptide versus 1.2 conventional care; baseline 1.1 | Surrogate marker, not a disease or survival endpoint |
| B-cell marker | CD20 percentages 12.0 ± 0.7 versus 12.0 ± 0.4; baseline 12.3 ± 0.6 | No corresponding generalized improvement across all immune measures |
Incompletely specified allocation, severity-dependent treatment and marker endpoints limit inference. These observations concern defined EDP; commercial Crystagen equivalence remains unverified.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Molecule. This family concerns the Glu-Asp-Pro sequence and proposed immune or geroprotective applications.
The sequence-level connection does not authenticate the composition or efficacy of a commercial Crystagen product.
- Publication
- US8057810B2 ↗ · 2011-11-15
- Earliest priority / filing
- 2006-05-30 / 2007-03-02
- Original applicant / assignee
- SIA Peptides OOO
- Indexed status
- Active · checked 2026-11-06
- Patent family
- 38314259 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Peptide substance revealing an immunogeroprotective effect, pharmaceutical composition on its base and the method of its application
Inventors: Vladimir Khatskelevich Khavinson; Evgeny Iosifovich Grigoriev; Vladimir Victorivich Malinin; Galina Anatolievna Ryzhak.
US8057810B2 · EP2032595B1 · KR101382947B1 · ATE513845T1 · DK2032595T3 · EA010575B1 · IL194499A0 · RU2301074C1 · UA91135C2 · WO2007139435A1
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- The sequence-level connection does not authenticate the composition or efficacy of a commercial Crystagen product.
- Incompletely specified allocation, severity-dependent treatment and marker endpoints limit inference. These observations concern defined EDP; commercial Crystagen equivalence remains unverified.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-38314259. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Vladimir Khatskelevich Khavinson, Evgeny Iosifovich Grigoriev, Vladimir Victorivich Malinin, Galina Anatolievna Ryzhak. Crystagen research trail: defined EDP peptide — US8057810B2 US8057810B2 · patent family 38314259 2011.
Molekul research summary: https://molekul.io/research/patent-us8057810b2. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry